Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lisata Therapeutics (LSTA) Asset Writedowns and Impairment (2016 - 2018)

Historic Asset Writedowns and Impairment for Lisata Therapeutics (LSTA) over the last 5 years, with Q2 2018 value amounting to -$1.4 million.

  • Lisata Therapeutics' Asset Writedowns and Impairment fell 117303.41% to -$1.4 million in Q2 2018 from the same period last year, while for Jun 2018 it was -$1.3 million, marking a year-over-year decrease of 20089.74%. This contributed to the annual value of $62.3 million for FY2015, which is 96304009.59% up from last year.
  • According to the latest figures from Q2 2018, Lisata Therapeutics' Asset Writedowns and Impairment is -$1.4 million, which was down 117303.41% from $128492.0 recorded in Q2 2017.
  • In the past 5 years, Lisata Therapeutics' Asset Writedowns and Impairment registered a high of $52.9 million during Q4 2015, and its lowest value of -$1.4 million during Q2 2018.
  • Moreover, its 5-year median value for Asset Writedowns and Impairment was $87896.5 (2017), whereas its average is $7.6 million.
  • Per our database at Business Quant, Lisata Therapeutics' Asset Writedowns and Impairment surged by 81768676.36% in 2015 and then crashed by 117303.41% in 2018.
  • Quarter analysis of 5 years shows Lisata Therapeutics' Asset Writedowns and Impairment stood at -$6467.0 in 2014, then surged by 817686.76% to $52.9 million in 2015, then plummeted by 101.12% to -$591307.0 in 2016, then skyrocketed by 121.73% to $128492.0 in 2017, then crashed by 1173.03% to -$1.4 million in 2018.
  • Its last three reported values are -$1.4 million in Q2 2018, $128492.0 for Q2 2017, and $47301.0 during Q1 2017.